New PCSK9 Inhibitor Allows 3-Month Treatment Intervals New PCSK9 Inhibitor Allows 3-Month Treatment Intervals

"It ' s a new antibody that has a long half-life so each treatment can be prolonged."MDedge News

Source: Medscape Cardiology Headlines - November 30, 2023 Category: Cardiology Tags: Cardiology News Source Type: news